Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does cardiac function modify left heart opacification with transpulmonary echo contrast agents?

H Völler1, K Schröder, C Spielberg

  • 1Department of Cardiopulmonology, Klinikum Steglitz, University of Berlin, Germany.

Echocardiography (Mount Kisco, N.Y.)
|December 9, 1992
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3D-printed porous tubular scaffolds enhance bone healing in rat femur defects: Effects of lumen diameter over time.

Biomaterials advances·2025
Same author

[Interstitial lung diseases : From imaging to treatment].

Radiologie (Heidelberg, Germany)·2024
Same author

Deletion of NADPH oxidase 2 in chondrocytes exacerbates ethanol-mediated growth plate disruption in mice without major effects on bone architecture or gene expression.

Alcohol, clinical & experimental research·2023
Same author

Nox4 promotes endothelial differentiation through chromatin remodeling.

Redox biology·2022
Same author

Retinal vascular occlusion in pregnancy: three case reports and a review of the literature.

Journal of medical case reports·2022
Same author

[Acute Respiratory Failure after Silicone Injection].

Pneumologie (Stuttgart, Germany)·2019

This study shows that the new echo contrast agent SH U 508-A provides similar left heart opacification in patients with normal and impaired ventricular function. Transit times were longer in patients with poor heart function, but the agent is safe for repeated use.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Pharmacology

Background:

  • Transpulmonary contrast echocardiography is a valuable tool for assessing cardiac function.
  • New contrast agents are needed to improve diagnostic capabilities.
  • SH U 508-A is a novel transpulmonary echo enhancing agent.

Purpose of the Study:

  • To evaluate the dependence of left heart opacification on ventricular function using SH U 508-A.
  • To assess the safety and efficacy of SH U 508-A in patients with varying cardiac function.
  • To determine the impact of ventricular function on the transit times and signal enhancement of SH U 508-A.

Main Methods:

  • Intravenous injection of SH U 508-A (400 mg/mL at 5, 9, 16 mL) in 10 patients (5 normal, 5 impaired ventricular function).

Related Experiment Videos

  • Visual assessment of signal enhancement.
  • Videodensitometric determination of peak intensity and duration of signal enhancement.
  • Measurement of transit times, systemic blood pressure, and heart rate.

    • Main Results:

    • No significant difference in visually assessed signal enhancement, peak intensity, or duration between groups.
    • Markedly prolonged transit times in patients with impaired ventricular function.
    • No significant alterations in systemic blood pressure or heart rate.
    • Transitory, dose-related side effects observed.

    Conclusions:

    • SH U 508-A provides consistent left heart opacification regardless of ventricular function.
    • Prolonged transit times in impaired function indicate potential for assessing ventricular performance.
    • The noninvasive nature and hemodynamic stability of SH U 508-A allow for repeated studies in diverse patient populations.